Identification of Expression Pattern and Clinical Significance of the Small Cajal Body-specific RNA SCARNA16 in Hepatocellular Carcinoma
Sitong Zhang,Yuan Ding,Zhongquan Sun,Yao Ge,Yanjie Li,Xin Han,Qianhui Xu,Liuzhi Zhou,Yining Chen,Hao Xu,Yang Bai,Chang Xu,Hao Ding,Sheng Yan,Weilin Wang
DOI: https://doi.org/10.14218/jcth.2021.00016
2022-01-01
Journal of Clinical and Translational Hepatology
Abstract:Background and Aims: For high morbidity and mortality, hepatocellular carcinoma (HCC) becomes a major health issue worldwide. Nowadays, numerous non-coding RNAs (ncRNAs) are known to regulate the occurrence and patho-genesis of tumors. Some ncRNAs have also been developed as tumor biomarkers and therapeutic targets. However, the potential function of the small Cajal body-specific RNA (scaRNA) SCARNA16, a newly identified ncRNA, remains to be explored in HCC. Methods: In both HCC cell lines and specimens from 120 enrolled patients, the expression val-ues of SCARNA16 were detected. We divided patients into SCARNA16 high and low expression subgroups, and then analyzed the difference of various clinical characteristics and prognosis data between subgroups. Results: Compared to paired controls, SCARNA16 was significantly down-regulated in HCC cell lines and clinical specimens (p<0.01). Besides, HCC patients with lower SCARNA16 expression commonly presented with larger and more tumor lesions, more ves-sel carcinoma emboli, more capsular invasion and higher TNM stages (p<0.05). Moreover, SCARNA16 expression was negatively correlated with postoperative prognosis of HCC patients in 5-year follow-up, including tumor-free survival (TFS) (median time of low vs. high subgroups: 14 vs. 48 months, p=0.006) and overall survival (OS) (median time of low vs. high subgroups: 39 vs. 52 months, p=0.001). Besides, SCARNA16 acted as an independent prognostic bio-marker in TFS (hazard ratio [HR]: 0.578, 95％ CI: 0.345–0.969, p=0.038) and OS (HR: 0.366, 95％ CI: 0.178–0.752, p=0.006). Conclusions: Low expression patterns of SCAR-NA16 remarkably associated with severe clinical status and poor survival of patients, suggesting that SCARNA16 pos-sesses potency as a novel biomarker for HCC.